alvimopan

Known as: alvimopan [Chemical/Ingredient], trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine 
A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
05101520012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Radical cystectomy (RC) for bladder cancer is frequently associated with delayed gastrointestinal (GI) recovery that… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Alvimopan, a mu-opioid antagonist without anti-analgesic effects, is being developed to manage postoperative ileus. We… (More)
Is this relevant?
2008
2008
BACKGROUND Post-operative ileus (POI) affects most patients undergoing abdominal surgery. AIM To evaluate the effect of… (More)
Is this relevant?
2008
2008
Postoperative ileus (POI) is a transient loss of coordinated peristalsis precipitated by surgery and exacerbated by opioid pain… (More)
  • table I
  • figure 1
  • table 2
Is this relevant?
2007
2007
OBJECTIVE To obtain further analysis regarding specific outcomes and alvimopan doses in bowel resection (BR) patients. SUMMARY… (More)
Is this relevant?
2007
2007
BACKGROUND Postoperative ileus (POI), an interruption of coordinated bowel motility after operation, is exacerbated by opioids… (More)
Is this relevant?
2007
2007
BACKGROUND Alvimopan is a selective, competitive mu-opioid receptor antagonist with limited oral bioavailability which may be… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Postoperative ileus presents significant clinical challenges that potentially prolong hospital stay, contribute to… (More)
Is this relevant?
2005
2005
UNLABELLED background & aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To demonstrate that alvimopan (6 or 12 mg) accelerates recovery of gastrointestinal (GI) function in patients… (More)
Is this relevant?